undamentalytics Newsletter

Shepard William R: insider trades

Director at CME Group. 23 open-market purchases and no sales not made under a pre-set plan, reported from August 20, 2010 to September 28, 2026.

Would copying Shepard William R’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 19 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on August 23, 2010 into $38,326 by November 2, 2026, +8.7% a year. The copy held shares only 43% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $38,360, +8.7% a year (the S&P 500 held throughout made $94,026, +14.9% a year). Beta against the index was 0.16. Twelve months after each report, the average purchase was −3.0% against the S&P 500 (median −5.0%), and 37% beat it. Measured from the trade date, the insider’s own timing, the average was −2.7%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$50.0k$100k 201020122014201620182020202220242026 $94.0k$38.4k$38.3k
Copying Shepard William RS&P 500, same days investedS&P 500, held throughout $10,000 copying Shepard William R’s open-market purchases from August 23, 2010, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+8.7%
S&P 500, same days invested
+8.7% (held throughout +14.9%)
Time in shares
43%
Sharpe ratio (S&P 500)
0.53 (0.81)
Biggest drop (S&P 500)
−31% (−34%)
Market sensitivity (beta)
0.16
Purchases copied
23

Trade by trade

Shepard William R: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 22 +0.1% +2.2% 55% 8 0.15 0.89 No reliable evidence
Purchases, 6 months after the report 21 −3.6% −3.5% 48% 8 −0.99 0.35 No reliable evidence
Purchases, 12 months after the report 19 −3.0% −5.0% 37% 7 −0.07 0.95 No reliable evidence
Purchases, 12 months after the trade 19 −2.7% −6.5% 47% 7 −0.61 0.56 No reliable evidence
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
CME Group CME —230August 20, 2010September 28, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 28, 2026September 25, 2026 CME Purchase $78,626 not yetnot yetnot yet
June 29, 2026June 25, 2026 CME Purchase $78,186 +17.2%not yetnot yet
March 30, 2026March 26, 2026 CME Purchase $437,101 −36.3%not yetnot yet
January 2, 2026December 30, 2025 CME Purchase $73,008 +19.5%not yetnot yet
September 26, 2025September 25, 2025 CME Purchase $72,673 −1.2%−16.2%−15.8%
June 26, 2025June 25, 2025 CME Purchase $72,337 −9.1%−39.3%−37.3%
March 27, 2025March 26, 2025 CME Purchase $71,995 −5.9%−1.4%+3.3%
January 17, 2025January 16, 2025 CME Purchase $325,798 +27.2%+7.9%+6.9%
December 30, 2024December 27, 2024 CME Purchase $64,285 +24.3%+2.0%+3.2%
September 27, 2024September 25, 2024 CME Purchase $63,946 +5.2%+7.6%+12.9%
June 26, 2024June 25, 2024 CME Purchase $63,569 +7.3%+32.8%+33.7%
March 27, 2024March 26, 2024 CME Purchase $63,232 −12.5%+18.8%+20.4%
January 19, 2024January 18, 2024 CME Purchase $281,369 +2.9%−7.6%−8.4%
December 29, 2023December 28, 2023 CME Purchase $58,646 −8.4%−8.9%−10.1%
October 6, 2023September 27, 2023 CME Purchase $58,325 −15.9%−27.8%−21.9%
June 28, 2023June 27, 2023 CME Purchase $57,972 +12.4%−14.5%−12.6%
March 29, 2023March 27, 2023 CME Purchase $93,966 −11.5%−11.3%−11.8%
January 20, 2023December 28, 2022 CME Purchase $279,347 +4.6%−0.2%+3.4%
November 8, 2022November 4, 2022 CME Purchase $8,269,650 +1.6%+13.8%+12.8%
June 12, 2020June 11, 2020 CME Purchase $218,885 −15.1%−12.2%−16.3%
June 4, 2020June 2, 2020 CME Purchase $137,315 −18.8%−17.1%−13.7%
June 27, 2017March 12, 2012 CME Purchase $30,122 +3.5%+21.4%+7.1%
August 20, 2010August 19, 2010 CME Purchase $1,225,000 +11.9%−5.0%−6.5%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Shepard William R traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.